Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Published:2005-01 Issue:1 Volume:23 Page:39-49
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Bence Aimee K.,Anderson Eric B.,Halepota Maqbool A.,Doukas Michael A.,DeSimone Phillip A.,Davis George A.,Smith Deborah A.,Koch Kevin M.,Stead Andrew G.,Mangum Steve,Bowen Carolyn J.,Spector Neil L.,Hsieh Showchien,Adams Val R.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration;Journal of Veterinary Medical Science;2024

2. The effect of shikonin on the metabolism of lapatinib in vitro, and in vivo;Toxicology and Applied Pharmacology;2024-01

3. Complex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer;Journal of Drug Delivery Science and Technology;2023-04

4. Lapatinib: A comprehensive profile;Profiles of Drug Substances, Excipients and Related Methodology;2023

5. Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity;Immunologic Research;2022-07-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP